UniProt ID | CDK4_HUMAN | |
---|---|---|
UniProt AC | P11802 | |
Protein Name | Cyclin-dependent kinase 4 | |
Gene Name | CDK4 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 303 | |
Subcellular Localization | Cytoplasm. Nucleus. Membrane. Cytoplasmic when non-complexed. Forms a cyclin D-CDK4 complex in the cytoplasm as cells progress through G(1) phase. The complex accumulates on the nuclear membrane and enters the nucleus on transition from G(1) to S pha | |
Protein Description | Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.. | |
Protein Sequence | MATSRYEPVAEIGVGAYGTVYKARDPHSGHFVALKSVRVPNGGGGGGGLPISTVREVALLRRLEAFEHPNVVRLMDVCATSRTDREIKVTLVFEHVDQDLRTYLDKAPPPGLPAETIKDLMRQFLRGLDFLHANCIVHRDLKPENILVTSGGTVKLADFGLARIYSYQMALTPVVVTLWYRAPEVLLQSTYATPVDMWSVGCIFAEMFRRKPLFCGNSEADQLGKIFDLIGLPPEDDWPRDVSLPRGAFPPRGPRPVQSVVPEMEESGAQLLLEMLTFNPHKRISAFRALQHSYLHKDEGNPE | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MATSRYEPV ------CCCCCCCCC | 17.81 | 19413330 | |
17 | Phosphorylation | AEIGVGAYGTVYKAR EEEECEECEEEEEEC | 13.85 | 22817900 | |
22 | Ubiquitination | GAYGTVYKARDPHSG EECEEEEEECCCCCC | 32.39 | 21906983 | |
22 | Ubiquitination | GAYGTVYKARDPHSG EECEEEEEECCCCCC | 32.39 | - | |
28 | Phosphorylation | YKARDPHSGHFVALK EEECCCCCCCEEEEE | 39.07 | 20873877 | |
35 | Ubiquitination | SGHFVALKSVRVPNG CCCEEEEEEEECCCC | 36.85 | 21890473 | |
35 | Ubiquitination | SGHFVALKSVRVPNG CCCEEEEEEEECCCC | 36.85 | 21890473 | |
35 | Ubiquitination | SGHFVALKSVRVPNG CCCEEEEEEEECCCC | 36.85 | 21890473 | |
35 | Ubiquitination | SGHFVALKSVRVPNG CCCEEEEEEEECCCC | 36.85 | 21906983 | |
91 | Ubiquitination | DREIKVTLVFEHVDQ CCEEEEEEEEEECCH | 4.68 | - | |
101 | Methylation | EHVDQDLRTYLDKAP EECCHHHHHHHHHCC | 29.61 | - | |
102 | Phosphorylation | HVDQDLRTYLDKAPP ECCHHHHHHHHHCCC | 35.42 | 20071362 | |
103 | Phosphorylation | VDQDLRTYLDKAPPP CCHHHHHHHHHCCCC | 13.38 | 29496907 | |
106 | Ubiquitination | DLRTYLDKAPPPGLP HHHHHHHHCCCCCCC | 61.26 | 21906983 | |
118 | Ubiquitination | GLPAETIKDLMRQFL CCCHHHHHHHHHHHH | 52.83 | 21906983 | |
142 | Ubiquitination | CIVHRDLKPENILVT EEECCCCCHHHEEEE | 55.35 | 21906983 | |
150 | Phosphorylation | PENILVTSGGTVKLA HHHEEEECCCEEEHH | 27.96 | 20873877 | |
153 | Phosphorylation | ILVTSGGTVKLADFG EEEECCCEEEHHHHC | 20.28 | 20873877 | |
155 | Ubiquitination | VTSGGTVKLADFGLA EECCCEEEHHHHCHH | 37.48 | 21906983 | |
165 | Phosphorylation | DFGLARIYSYQMALT HHCHHHHEEHHHCCC | 8.86 | 25262027 | |
166 | Phosphorylation | FGLARIYSYQMALTP HCHHHHEEHHHCCCC | 13.40 | 25262027 | |
167 | Phosphorylation | GLARIYSYQMALTPV CHHHHEEHHHCCCCH | 5.83 | 25262027 | |
169 | Sulfoxidation | ARIYSYQMALTPVVV HHHEEHHHCCCCHHH | 2.21 | 28183972 | |
172 | Phosphorylation | YSYQMALTPVVVTLW EEHHHCCCCHHHHHH | 12.42 | 9311594 | |
177 | Phosphorylation | ALTPVVVTLWYRAPE CCCCHHHHHHHCCCH | 10.44 | 25262027 | |
177 | Ubiquitination | ALTPVVVTLWYRAPE CCCCHHHHHHHCCCH | 10.44 | - | |
180 | Phosphorylation | PVVVTLWYRAPEVLL CHHHHHHHCCCHHHH | 10.46 | 25262027 | |
211 | Ubiquitination | FAEMFRRKPLFCGNS HHHHHHCCCCCCCCC | 41.64 | 21890473 | |
243 | Phosphorylation | DDWPRDVSLPRGAFP CCCCCCCCCCCCCCC | 36.62 | 24719451 | |
277 | Phosphorylation | QLLLEMLTFNPHKRI HHHHHHHHCCHHHHH | 21.76 | 20071362 | |
282 | Ubiquitination | MLTFNPHKRISAFRA HHHCCHHHHHHHHHH | 53.32 | - | |
285 | Phosphorylation | FNPHKRISAFRALQH CCHHHHHHHHHHHHH | 25.95 | 24719451 | |
293 | Phosphorylation | AFRALQHSYLHKDEG HHHHHHHHHHCCCCC | 19.21 | 20873877 | |
297 | Ubiquitination | LQHSYLHKDEGNPE- HHHHHHCCCCCCCC- | 55.68 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
17 | Y | Phosphorylation | Kinase | LYN | P07948 | PSP |
17 | Y | Phosphorylation | Kinase | SRC | P12931 | PSP |
17 | Y | Phosphorylation | Kinase | YES1 | P07947 | GPS |
17 | Y | Phosphorylation | Kinase | SRC-FAMILY | - | GPS |
172 | T | Phosphorylation | Kinase | CDK7 | P50613 | PSP |
172 | T | Phosphorylation | Kinase | MAPK8 | P45983 | GPS |
172 | T | Phosphorylation | Kinase | MAPK9 | P45984 | GPS |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of CDK4_HUMAN !! |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-150 AND THR-172, ANDMASS SPECTROMETRY. | |
"The structure of CDK4/cyclin D3 has implications for models of CDKactivation."; Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A.,Noble M.E.; Proc. Natl. Acad. Sci. U.S.A. 106:4171-4176(2009). Cited for: X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF NONPHOSPHORYLATED FORM INCOMPLEX WITH CCND3, PHOSPHORYLATION AT THR-172, AND MASS SPECTROMETRY. | |
"Crystal structure of human CDK4 in complex with a D-type cyclin."; Day P.J., Cleasby A., Tickle I.J., O'Reilly M., Coyle J.E.,Holding F.P., McMenamin R.L., Yon J., Chopra R., Lengauer C.,Jhoti H.; Proc. Natl. Acad. Sci. U.S.A. 106:4166-4170(2009). Cited for: X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF THR-172-PHOSPHORYLATED WILDTYPE AND MUTANTS ALA-172; PHE-172 AND ASP-172 IN COMPLEX WITH CCND1,MASS SPECTROMETRY, PHOSPHORYLATION AT THR-172, AND CATALYTIC ACTIVITY. | |
"Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6,evidence that CDK4 might not be activated by CDK7, and design of aCDK6 activating mutation."; Bockstaele L., Bisteau X., Paternot S., Roger P.P.; Mol. Cell. Biol. 29:4188-4200(2009). Cited for: PHOSPHORYLATION AT THR-172, ENZYME REGULATION, AND MUTAGENESIS OFPRO-173. | |
"Regulated activating Thr172 phosphorylation of cyclin-dependentkinase 4(CDK4): its relationship with cyclins and CDK 'inhibitors'."; Bockstaele L., Kooken H., Libert F., Paternot S., Dumont J.E.,de Launoit Y., Roger P.P., Coulonval K.; Mol. Cell. Biol. 26:5070-5085(2006). Cited for: PHOSPHORYLATION AT THR-172, INTERACTION WITH CCND1; CCND3; CDKN2A ANDCDKN1B, AND MUTAGENESIS OF THR-172. |